Akebia Therapeutics (AKBA) Income from Continuing Operations (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Income from Continuing Operations data on file, last reported at 9054000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 248.13% year-over-year to 9054000.0 in Q1 2026; TTM through Mar 2026 was 20511000.0, a 54.73% increase from a year earlier, with the FY2025 full-year figure at 5345000.0, up 92.3% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 9054000.0, up from 12244000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for AKBA reached as high as 31375000.0 in Q2 2022 and fell as low as 62281000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 13133352.94 across 5 years, with a median of 11172000.0 in 2023.
• Across the five-year window, Income from Continuing Operations soared 138.24% in 2022 and sank 3814.01% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 4124000.0 in 2022, then surged by 114.89% to 614000.0 in 2023, then sank by 3814.01% to 22804000.0 in 2024, then soared by 46.31% to 12244000.0 in 2025, then rose by 26.05% to 9054000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 9054000.0 in Q1 2026, 12244000.0 in Q4 2025, and 540000.0 in Q3 2025.